Your browser doesn't support javascript.
loading
Myocardial Fibrosis in Hypertrophic Cardiomyopathy: Volumetric Assessment of Late Enhancement Provided by Cardiac Computed Tomography.
Langer, Christoph; Schaefer, Philipp; Lutz, Matthias; Eden, Matthias; Hohnhorst, Mirko; Harders, Hauke; Faber, Lothar; Jansen, Olav; Both, Marcus; Frey, Norbert.
Afiliação
  • Langer C; From the *Department of Cardiology, Angiology and Intensive Care Medicine, Universitätsklinikum Schleswig-Holstein, Christian-Albrechts University of Kiel; †DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck; ‡Department of Diagnostic Radiology, Universitätsklinikum Schleswig-Holstein, Christian-Albrechts University of Kiel, Kiel; and §Department of Cardiology, Heart and Diabetes Center North Rhine-Westphalia, University Clinic of the Ruhr-University Bochum, Bad O
J Comput Assist Tomogr ; 39(5): 797-803, 2015.
Article em En | MEDLINE | ID: mdl-26125299
ABSTRACT

INTRODUCTION:

With subgroups of patients with hypertrophic cardiomyopathy (HCM) confers a 4% to 5% risk for adverse prognosis. Besides left-ventricular muscle mass (LV-MM) myocardial fibrosis (MF) assessable by late gadolinium enhancement in cardiovascular magnetic resonance (LGE-CMR) has been related to that. Myocardial fibrosis can also be demonstrated by late enhancement (LE) in late-enhanced multislice computed tomography (leMDCT). This analysis investigates leMDCT whether to enable quantification of LE load in terms of LE mass by percent LV-MM in HCM.

METHODS:

In a prospective validation study, we included 30 consecutive patients with HCM who underwent leMDCT (64 slice) and LGE-CMR (1.5 T). The leMDCT scan was performed 7 minutes after injection of iodine contrast (Iopromid). Endocardial and epicardial planimetry served for the assessment of LV-MM. Visually detectable LE was quantified using the manual quantification method resulting in LE by percent LV-MM (%LE). The LGE-CMR data served for validation.

RESULTS:

Mean (SD) age was 64.1 (13.9) years. Myocardial fibrosis prevalence was 63.3% (19/30 patients indentified by both leMDCT and LGE-CMR). In leMDCT, tissue density in LE areas compared with normal myocardium was higher (138.2 [23.9] HU vs 98.4 [16.5] HU, P < 0.001) but lower than in the LV cavity (138.2 [23.9] HU vs 169.2 [35.9] HU, P < 0.001). Late enhancement mass in leMDCT seemed to be 7.9 (8.5) g LE versus 8.6 [11] g LGE in CMR (P = 0.497, r = 0.95) resulting in a leMDCT/LGE-CMR relation of 1.2. Referring LE mass to LV-MM gave an LE proportion measured by leMDCT of 4 (3.9) %LE versus 3.9 (4.1) %LGE in LGE-CMR (r = 0.88, P = 0.75). Intraobserver/interobserver reliability of LE mass assessment showed an intraclass correlation coefficient of 0.99 and 0.97.

CONCLUSIONS:

In patients with HCM, leMDCT provides volumetric assessment of LE mass-absolutely and by percent LV-MM.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cardiomiopatia Hipertrófica / Tomografia Computadorizada Multidetectores / Miocárdio Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cardiomiopatia Hipertrófica / Tomografia Computadorizada Multidetectores / Miocárdio Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article